Castle Biosciences (CSTL) Osake Kurssi
Castle Biosciences Kurssi
Liikevaihto on kasvanut 52,0 % vuodessa viimeisten 8 vuoden aikana 344,14 M USD:een. Castle Biosciencesn nettomarginaali on nyt −7,0 %, noussut −33,3 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 40,00 USD, eli yli nykyhintaa 22,1 %. 16 analyytikosta 15 suosittaa ostoa — kokonaiskonsensus on Osta.
Castle Biosciences osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Castle Biosciences liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Castle Biosciences -osakkeesta
The business model of Castle Biosciences Inc revolves around providing diagnostic and prognostic solutions for patients with skin and other cancers. By leveraging advanced genomic technology, the company offers diagnostic tests that assess the risk, recurrence, and progression of various cancers. Castle Biosciences focuses on developing and commercializing molecular diagnostic tests that aid in personalized treatment decisions for cancer patients. With a patient-centric approach, the company aims to improve patient outcomes and contribute to the advancement of precision medicine. Castle Biosciences Inc is dedicated to revolutionizing cancer management through innovative diagnostics.
Castle Biosciences Inc is primarily active in the healthcare industry, specifically in the field of precision medicine. The company specializes in developing and commercializing molecular diagnostics tests that provide personalized genomic information to aid in the diagnosis and treatment of various types of cancer. Castle Biosciences Inc's innovative solutions help healthcare professionals make informed decisions about patient care by assessing the likelihood of disease recurrence and determining optimal treatment plans. With a focus on improving patient outcomes, Castle Biosciences Inc is dedicated to advancing precision medicine in oncology.
The main competitors of Castle Biosciences Inc in the market are Myriad Genetics, Genomic Health, and NanoString Technologies.
Castle Biosciences Inc is a leading precision oncology company that specializes in molecular diagnostics. Established in 2008, the company is dedicated to providing personalized medicine solutions for patients with challenging cancers. With a focus on dermatologic cancers, Castle Biosciences utilizes advanced genomic and proteomic technology to develop innovative diagnostic tests. Their flagship product, DecisionDx-Melanoma, is a powerful tool that assesses the risk and prognosis of melanoma patients. Castle Biosciences Inc has a strong commitment to research, collaboration, and improving patient outcomes. With their cutting-edge technology and expertise, the company continues to revolutionize cancer diagnostics and treatment strategies.
Castle Biosciences Inc has achieved several significant milestones since its inception. The company pioneered the development of DecisionDx®-Melanoma, a groundbreaking gene expression profile test, which has revolutionized the management of melanoma patients. Castle Biosciences Inc has also expanded its product portfolio with DecisionDx®-UM, a test for uveal melanoma, providing accurate prognostic information for physicians and patients. In addition, the company has received numerous awards and recognitions for its innovative approach to personalized medicine, further establishing its leadership in the field. Castle Biosciences Inc continues to drive advancements in genomic diagnostics, improving patient outcomes and transforming cancer care.
Castle Biosciences Inc is primarily present in the United States.
Castle Biosciences Inc represents values such as innovation, accuracy, and patient-centricity. With a strong corporate philosophy centered around precision medicine, the company utilizes advanced genomic technology to provide actionable, personalized information to aid healthcare decisions for patients with underserved cancers. Castle Biosciences Inc is committed to improving patient outcomes through its proprietary diagnostic tests that offer valuable insights into the individual biology of each patient. By combining science, research, and a patient-first approach, Castle Biosciences Inc strives to empower healthcare providers and patients with the necessary tools to make informed, targeted treatment decisions.
Analyytikot asettavat tällä hetkellä Castle Biosciences-osakkeelle keskimääräisen tavoitehinnan 39,00 USD (mediaani: 40,00 USD), mikä merkitsee +19,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 16 analyytikkoarvioon.
16 analyytikkoa arvioi tällä hetkellä Castle Biosciences-osaketta: 15 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Castle Biosciences-yhtiöltä 392,28 M USD liikevaihtoa ja −0,84 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Castle Biosciences-osake noteerataan hintaan 29,76 EUR (32,75 USD).
Castle Biosciences-osake (CSTL) on listattuna 1 pörssissä, muun muassa: NASDAQ (CSTL).
Castle Biosciences Inc is a biotechnology company that develops and distributes diagnostic tests and genetic analyses. The company is headquartered in Friendswood, Texas, USA and has been operating in the industry since 2007. The main task of Castle Biosciences is to develop clinically accurate prediction tools to assess the progression of tumors and consider them in patient treatment. For this purpose, the company has developed a range of test procedures based on a combination of genotyping, proteomics, and immuno-sensing methods. The key product of Castle Biosciences is the Prognostic Test, which provides an accurate assessment of the risk of skin cancer. The test uses molecular markers to predict the risk of melanoma or ocular melanoma and determine if therapy is necessary. Another product is DecisionDx-UM, a powerful diagnostic assay that aids in the prognosis of malignant uveal melanoma (UM). In combination with standardized clinical factors such as age, gender, and tumor size, DecisionDx-UM is an important indicator of disease progression as well as promising treatment approaches. Castle Biosciences offers a wide range of proteomic analyses tailored to the needs of the patient. These tests are used to estimate the risk of cancer and enable treating physicians to develop treatment and follow-up strategies. The company also conducts a number of research and development initiatives aimed at understanding the molecular basis of cancer and developing novel diagnostic tests and therapies. The goal is to make groundbreaking scientific discoveries to identify new and improved molecular markers that can be used to assess disease progression and the efficacy of therapies. Overall, Castle Biosciences provides an advanced and accurate platform for cancer diagnostics that can help patients and doctors make better-informed decisions. The company is dedicated to further exploring the molecular basis of cancer and developing more innovative diagnostic tools to improve patient care worldwide. In summary, the business model of Castle Biosciences is focused on the development and marketing of diagnostic tools for cancer treatment. The company offers a wide range of molecular, proteomic, and immuno-sensing analyses that enable accurate prognosis of tumor progression. The company also conducts extensive research and development initiatives to discover new molecular markers for the diagnosis and treatment of cancer.
odotettu liikevaihto Castle Biosciences on 392,28 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Castle Biosciences on −24,52 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Castle Biosciences:n hinta-voitto-suhde (P/E) on tällä hetkellä −39,18. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Castle Biosciences-osakkeen arvostusta.
Castle Biosciences:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,45. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Castle Biosciences-osakkeen arvostuskennuslukuna.
Castle Biosciences:n Eulpool-laatuscore on 4/10.
Castle Biosciences:n ISIN on US14843C1053. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Castle Biosciences:n WKN on A2PNH3. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Castle Biosciences:n ticker on CSTL. Tämä pörssinoteeraus käytetään Castle Biosciences-osakkeiden kauppaan pörssissä.
Castle Biosciences osake
Castle Biosciences vertaisryhmä
Castle Biosciences Ticker
Castle Biosciences FIGI
Kaikki tunnusluvut ja syvällinen analyysi Castle Biosciences:sta
Meidän osakeanalyysimme Castle Biosciences-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Castle Biosciences:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: